Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery
Proposed Schedule III drug classification expected to de-risk Cannasoul’s cannabis research and potential regulatory pathways
NEW YORK, May 7, 2024 /PRNewswire/ — Synaptogenix, Inc. (Nasdaq: SNPX)…